Press Releases Filter By Year 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 November 18, 2019 Valneva Reports Excellent Final Phase 1 Results for its Chikungunya Vaccine Candidate, Confirms Plans November 13, 2019 Valneva Announces Appointments of Two Leading Vaccine Experts to its Scientific Advisory Board October 31, 2019 Valneva Raises Product Sales Guidance Following Strong Nine-Month Results and R&D Execution September 30, 2019 Valneva Completes Recruitment for Phase 2 Studies of its Lyme Disease Vaccine Candidate VLA15 September 19, 2019 Valneva Confirms Delisting from the Vienna Stock Exchange August 19, 2019 Valneva Announces Management Board Stock Purchases August 1, 2019 Valneva Reports H1 2019 Results Marked by Strong Operational Performance and Major Corporate Progress July 29, 2019 Valneva Announces Formation of Scientific Advisory Board July 25, 2019 CEPI awards up to US$23.4 million to Valneva for late-stage development of a single-dose chikungunya vaccine July 16, 2019 Valneva Announces Drawdown of Further €10 million from its Existing European Investment Bank Loan 1 2 3 … 31
November 18, 2019 Valneva Reports Excellent Final Phase 1 Results for its Chikungunya Vaccine Candidate, Confirms Plans
November 13, 2019 Valneva Announces Appointments of Two Leading Vaccine Experts to its Scientific Advisory Board
October 31, 2019 Valneva Raises Product Sales Guidance Following Strong Nine-Month Results and R&D Execution
September 30, 2019 Valneva Completes Recruitment for Phase 2 Studies of its Lyme Disease Vaccine Candidate VLA15
August 1, 2019 Valneva Reports H1 2019 Results Marked by Strong Operational Performance and Major Corporate Progress
July 25, 2019 CEPI awards up to US$23.4 million to Valneva for late-stage development of a single-dose chikungunya vaccine
July 16, 2019 Valneva Announces Drawdown of Further €10 million from its Existing European Investment Bank Loan
